# Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.

> **NCT03993678** · PHASE1,PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 28 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** IP-001
- **DEVICE:** Thermal Ablation

## Key facts

- **NCT ID:** NCT03993678
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-12
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-07-19
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03993678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03993678, "Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03993678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*